The National Diabetes Audit (NDA) continues to provide a comprehensive view of Diabetes Care in England and Wales and measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales.
This national report presents the key findings and recommendations on care processes and treatment target achievement rates from 2013-2015 in all age groups in England and Wales along with information on offers and attendance for structured education places.
National Diabetes Inpatient Audit (NaDIA) 2015Laura Fargher
A easy read summary report about the quality of diabetes care in hospitals in England and Wales. Based on findings from the National Diabetes Inpatient Audit (2015).
Insights from the National Diabetes Registry: User SatisfactionArunah Chandran
The National Diabetes Registry (NDR) is a web-based application to register diabetes patients in Malaysia. It is used in all Ministry of Health (MOH) health clinics and selected hospitals.
User satisfaction is an important factor to determine quality and effectiveness of service delivery to clients of a particular product or service.
Our objective was to examine user satisfaction towards NDR system usage.
National Diabetes Registry Report 2013-2019: Update of Key FindingsArunah Chandran
This presentation is the update of key findings from the second National Diabetes Registry (NDR) report since the establishment of the registry in Malaysia. It is intended to share the data contained within the NDR for clinicians, public
health specialists and researchers and all those who are interested in the clinical management of diabetes
John Appleby, Chief Economist at The King's Fund, looks at the good, the bad and the inexplicable of NHS health care variations alongside our new report.
Read more about what information is available to help you and your organisation when managing long term conditions.
The HSCIC discussed this topic at HETT 2014, with reference to the following key areas:
- The national picture
- Population level health information
- Mental health minimum dataset
- CCG outcomes indicator set
- Quality and outcomes framework (QOF)
- The national diabetes audit
- Prescribing information
National Diabetes Inpatient Audit (NaDIA) 2015Laura Fargher
A easy read summary report about the quality of diabetes care in hospitals in England and Wales. Based on findings from the National Diabetes Inpatient Audit (2015).
Insights from the National Diabetes Registry: User SatisfactionArunah Chandran
The National Diabetes Registry (NDR) is a web-based application to register diabetes patients in Malaysia. It is used in all Ministry of Health (MOH) health clinics and selected hospitals.
User satisfaction is an important factor to determine quality and effectiveness of service delivery to clients of a particular product or service.
Our objective was to examine user satisfaction towards NDR system usage.
National Diabetes Registry Report 2013-2019: Update of Key FindingsArunah Chandran
This presentation is the update of key findings from the second National Diabetes Registry (NDR) report since the establishment of the registry in Malaysia. It is intended to share the data contained within the NDR for clinicians, public
health specialists and researchers and all those who are interested in the clinical management of diabetes
John Appleby, Chief Economist at The King's Fund, looks at the good, the bad and the inexplicable of NHS health care variations alongside our new report.
Read more about what information is available to help you and your organisation when managing long term conditions.
The HSCIC discussed this topic at HETT 2014, with reference to the following key areas:
- The national picture
- Population level health information
- Mental health minimum dataset
- CCG outcomes indicator set
- Quality and outcomes framework (QOF)
- The national diabetes audit
- Prescribing information
Three Dimensions of Care for Diabetes (3DFD) – diabetes management for people...NHS Improving Quality
Three Dimensions of Care for Diabetes (3DFD) – diabetes management for people with psychological / social needs, by King's College Hospital NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners
CDV: Still a National Priority, by Huon Gray, National Clinical Director (Cardiac), NHS England and Consultant Cardiologist, University Hospitals of Southampton
This webinar will discuss the prevalence of pre-diabetes and it’s contributing factors and the initial efforts to translate the National Diabetes Prevention Program to public health. We will also look at new approaches to providing interventions.
Learning objectives:
Scope and scale of pre-diabetes and what factors contribute to it.
Review initial efforts to translate the DPP to public health.
New approaches to providing interventions.
About The Presenter
Dr. Marrero received a B.A. (1974), M.A. (1978) and Ph.D. (1982) in Social Ecology from the University of California, Irvine. He joined the IU School of Medicine in 1984 and became the J.O. Ritchey Professor of Medicine in 2004. He was a member of the Diabetes Research & Training Center and served as Director of the Diabetes Prevention and Control Division. He is currently the Director of the Diabetes Translational Research Center. Dr. Marrero is an expert in the field of clinical trails in diabetes and translation research which moves scientific advances obtained in clinical trails into the public health sector. He helped design the Diabetes Prevention Program and the TRIAD study, which evaluated strategies to improve diabetes care delivery in managed care settings. His research interests include strategies for promoting diabetes prevention, care settings, improving diabetes care practices used by primary care providers, and the use of technology to facilitate care and education. Dr. Marrero was twice awarded the Allene Von Son Award for Diabetes Patient Education Tools by the American Association of Diabetes Educators, nominated to Who’s Who in Medicine and Health care in 2000, served as Associate Editor for Diabetes Care (1997-2002) and is currently the Associate Editor for Diabetes Forecast. He was selected as Alumni of the Year for University of California Irvine in 2006 and The Outstanding Educator in Diabetes in 2008 by the American Diabetes Association. He is the current President of the American Diabetes Association.
Physical Health Action at Last! by Karen Conlon, SMI Project Lead, Mike Leonard, clinical Pharmacist and Pauline Smith, Physical Healthcare Project Nurse
Improving the physical health of patients with severe mental health illness ...NHS Improving Quality
Improving the physical health of patients with severe mental health illness in primary care, by Rhiannon England, GP Clinical Lead, City and Hackney CCG
CentreLearn Solutions - online training for fire departments and EMS agenciesGreg Friese
Learn about the CentreLearn Solutions learning management system, the premier online training for fire departments and EMS agencies. With an industry leading course library and unparalleled customer support your department can begin training online quickly. Many features allow automation of tasking and reporting. CECBEMS approved CE courses for EMTs and Paramedics, as well as a large library of courses for firefighters will help your organization meet its annual training requirements
Three Dimensions of Care for Diabetes (3DFD) – diabetes management for people...NHS Improving Quality
Three Dimensions of Care for Diabetes (3DFD) – diabetes management for people with psychological / social needs, by King's College Hospital NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners
CDV: Still a National Priority, by Huon Gray, National Clinical Director (Cardiac), NHS England and Consultant Cardiologist, University Hospitals of Southampton
This webinar will discuss the prevalence of pre-diabetes and it’s contributing factors and the initial efforts to translate the National Diabetes Prevention Program to public health. We will also look at new approaches to providing interventions.
Learning objectives:
Scope and scale of pre-diabetes and what factors contribute to it.
Review initial efforts to translate the DPP to public health.
New approaches to providing interventions.
About The Presenter
Dr. Marrero received a B.A. (1974), M.A. (1978) and Ph.D. (1982) in Social Ecology from the University of California, Irvine. He joined the IU School of Medicine in 1984 and became the J.O. Ritchey Professor of Medicine in 2004. He was a member of the Diabetes Research & Training Center and served as Director of the Diabetes Prevention and Control Division. He is currently the Director of the Diabetes Translational Research Center. Dr. Marrero is an expert in the field of clinical trails in diabetes and translation research which moves scientific advances obtained in clinical trails into the public health sector. He helped design the Diabetes Prevention Program and the TRIAD study, which evaluated strategies to improve diabetes care delivery in managed care settings. His research interests include strategies for promoting diabetes prevention, care settings, improving diabetes care practices used by primary care providers, and the use of technology to facilitate care and education. Dr. Marrero was twice awarded the Allene Von Son Award for Diabetes Patient Education Tools by the American Association of Diabetes Educators, nominated to Who’s Who in Medicine and Health care in 2000, served as Associate Editor for Diabetes Care (1997-2002) and is currently the Associate Editor for Diabetes Forecast. He was selected as Alumni of the Year for University of California Irvine in 2006 and The Outstanding Educator in Diabetes in 2008 by the American Diabetes Association. He is the current President of the American Diabetes Association.
Physical Health Action at Last! by Karen Conlon, SMI Project Lead, Mike Leonard, clinical Pharmacist and Pauline Smith, Physical Healthcare Project Nurse
Improving the physical health of patients with severe mental health illness ...NHS Improving Quality
Improving the physical health of patients with severe mental health illness in primary care, by Rhiannon England, GP Clinical Lead, City and Hackney CCG
CentreLearn Solutions - online training for fire departments and EMS agenciesGreg Friese
Learn about the CentreLearn Solutions learning management system, the premier online training for fire departments and EMS agencies. With an industry leading course library and unparalleled customer support your department can begin training online quickly. Many features allow automation of tasking and reporting. CECBEMS approved CE courses for EMTs and Paramedics, as well as a large library of courses for firefighters will help your organization meet its annual training requirements
Marketing de Contenidos - Cómo atraer clientesMaking Contents
Presentación de Making Contents, la agencia peruana de marketing de contenidos, en el Seminario de Inbound Marketing en el Centro de Convenciones de la UTP de Lima (22.07.2016)
Diabetes mellitus is a major global public health problem. The rise in global prevalence is expected to reach 5.4% or 300 million worldwide by 2025, with developed countries carrying a larger burden (1). Malaysia is not spared from this phenomena, with an alarming rise in prevalence of Type 2 diabetes mellitus (T2DM) over the past fifteen years, from 8.3% (NHMS 1, 1996) to 20.8% (NHMS IV, 2011) (2). What is most worrying is the figure for undiagnosed diabetics, which recorded almost a ten-fold increase (from 1.8% to 10.1%) within the same period. The national economic burden for provision of ambulatory or outpatient care for diabetes patients alone was estimated to cost the Ministry of Health RM 836 million, which took up 2.2% of the nation’s total health expenditure for 2009 (3). The average provider cost per outpatient visit for diabetes treatment at primary care was RM393.24, compared to RM 2707.44 at Specialist diabetic clinics. Treatment at primary care health centres was also highly cost effective compared to Specialist diabetic clinics (4). Due to the chronic nature of the disease, its many related complications and the progress in medical expertise, the costs to provide health care for the this group can only be expected to escalate in years to come. Strategies to effectively treat the chronic diseases (i.e. NCDs and T2DM) have been in place since the 1990s, however, the National Strategic Planning for Non-Communicable Diseases, (NSPNCD)(5) recommends that efforts should be channeled towards primary prevention, early NCD risk factor identification and NCD risk factor intervention or “clinical preventive services”. The clinical preventive services however, need to be emphasised, as early preventive measures can reduce long-term complications and morbidity related to diabetes. The risk factors which should trigger clinicians to provide clinical preventive measures include: obesity, sedentary lifestyles, dietary indiscretions, elderly (for late onset diabetes, pancreas insufficiency), family history of diabetes (risk in offspring of one diabetic parent: 30%, both parents: 60%). The 10th Malaysian Plan : Country Health Plan aims to restructure the national healthcare financing and healthcare delivery system to ensure universal health coverage of healthcare services to be provided at minimal cost using the existing infrastructure in delivering continuity of care across programmes, across healthcare settings and across healthcare providers (6). To reduce the fragmentation of care which commonly occurs in most NCD programmes, there is a need to involve healthcare providers within the healthcare service to be orientated in their roles and contribution in providing a seamless long-term care programme. It is hoped that this effort will benefit not only the patients but also provide relevant feedback on quality of healthcare service provision by the stakeholders. The current public health centre set up which combines Outpatient Primary Care
Results of an impact evaluation on professional competences accreditation of general practitioners in primary care
26th International Conference. The International Society for Quality in Health Care
Dublin 11th - 14th October 2009
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
National Diabetes Audit (NDA) Care Processes and Treatment Targets 2013-15
1. National Diabetes Audit
2013-2014 and 2014-2015
Report 1: Care Processes and Treatment Targets
• Version 1.0
• Published: 28 January 2016
2. Introduction
The National Diabetes Audit (NDA) continues to provide a comprehensive view
of Diabetes Care in England and Wales and measures the effectiveness of
diabetes healthcare against NICE Clinical Guidelines and NICE Quality
Standards1,2 in England and Wales. This report covers two years because of
the acceleration programme to bring publication forward.
GP Practice and specialist service level information accompanies this report
and can be found here. This provides casemix adjusted bandings for each of
the care processes. They show whether a service is achieving care process
delivery and treatment target achievement at levels expected for their patient
population. The bandings take into account age, gender, ethnicity, duration of
diabetes and social deprivation.
The banding is not a measure of quality of care. A higher or lower than
expected number of people completing care processes, should not immediately
be interpreted as indicating good or poor performance. Instead it should be
viewed as an alert which requires further investigation.
21,2 . Please see full list of footnotes in the definitions and footnote section (page 36)
3. Introduction
Participation of GP practices is variable across the country. This may be due to
the varied levels of support for participation offered to GP practices by Clinical
Commissioning Groups (CCGs) following the increased complexity of
registration and submission imposed by the new Information Governance ‘opt
in’ requirements.
Participation for 2014-15 was around 4,700 GP practices (57 per cent) and 99
specialist services capturing information on 1.9 million people with diabetes.
Bill Taylor, Clinical Lead Quality Improvement, Clinical Innovation and Research Centre,
Royal College of General Practitioners
3
“The NDA report is a very useful data source for identifying in which areas of
diabetes care there are potential for improvement in general practice. The majority
of the data is comparable with QOF which is already in the public domain, however
it is a rich source of more detailed information and is presented in a different, clear
and easy to compare format. The National Audit itself collects data from primary
and secondary care"
4. Key Findings
• There are encouraging trends of improvement in blood
pressure control for people with Type 1 and Type 2
diabetes and glucose control for Type 1 diabetes.
• People aged under 40 are much less likely to receive
their care processes and those under 65 are less likely
to achieve their treatment targets.
• There remain appreciable variations in care process
completion and treatment target achievement between
practices, between specialist services and between
CCGs/LHBs.
4
5. We recommend that:
People with diabetes
• Attend invitations for annual care process checks with your GP or specialist
service.
• Work with doctors and nurses to achieve the NICE recommended treatment
targets.
Care Providers (General Practices and Specialist Services)
• Sustain focus on improving glucose and blood pressure control.
• Investigate reasons for underachievement in people of working age and
younger. Consider new systems that could increase engagement.
Clinical Commissioning Groups (CCGs) and Local Health Boards (LHBs)
• Support all diabetes care providers to participate in the audit.
• Investigate reasons for CCG and GP/Specialist underachievement. Provide
forums for shared learning from better performers.
5
6. National Diabetes Audit 2014-15
6
Is everyone with
diabetes diagnosed and
recorded on a practice
diabetes register?
7. Participation
7
Audit Year Total number of
practices
Number of
participating
practices
National participation
rate
2012-13 8,476 5,991 70.7%
2013-14 8,232 4,699 57.1%
2014-15 8,198 4,696 57.3%
Key Finding
The overall number of General Practices participating in the
2013-14 / 2014-15 NDA is lower than in previous years, but
there is significant variation between CCG/LHB’s.
Table 1: Practice participation by audit year
8. Participation: Comment
The wide variation may be due to differences in local
prioritisation. More than a fifth of the CCGs/LHBs
achieved over 90 per cent participation; 19 CCGs
and 4 LHBs achieved 100 per cent in 2014-15.
8
Recommendations:
• CCGs and LHBs should support GP practices to participate in
the audit
• CCGs and LHBs with low participation should network with
those who have high participation to understand how best to
deliver the right encouragement and support
• CCGs and LHBs with low participation should consider the value
of high participation for high quality diabetes care
9. Registrations
9
Audit Year Total number
of
registrations
Percentage of
the
population*
Registrations
from Primary
Care
Registrations from
Specialist Care
where GP not a
participant
2012-13 2,075,123 4.9% 1,997,467 77,656
2013-14 1,763,446 4.8% 1,682,818 80,628
2014-15 1,894,887 5.1% 1,811,496 83,391
Key Finding
The audit collects information from both primary care and
secondary care; the vast majority of patients are registered in
primary care with only a small number of patients (4.4 per cent)
appearing only in secondary care submissions.
* Population is the participating GP practices list size
Table 2: Diabetes registrations and prevalence for all diabetes in England and
Wales by source and audit year
10. National Diabetes Audit 2014-15
10
What percentage of people
registered with diabetes
received the NICE key
processes of diabetes care?
11. Care Processes
11
All people with diabetes aged 12 years and over should receive all of the
nine, NICE recommended care processes1,2 and attend a structured
education program when diagnosed.
Nine Annual Care Processes for all people with diabetes age 12 and over
Responsibility of Diabetes Care Providers (included in the NDA 8 Care Processes)
1 - HbA1c
(blood test for glucose control)
5 - Urine Albumin/Creatinine Ratio
(urine test for kidney function)
2 - Blood Pressure
(measurement for cardiovascular risk)
6 - Foot Risk Surveillance
(foot examination for foot ulcer risk)
3 - Serum Cholesterol
(blood test for cardiovascular risk)
7 - Body Mass Index
(measurement for cardiovascular risk)
4 - Serum Creatinine
(blood test for kidney function)
8 - Smoking History
(question for cardiovascular risk)
Responsibility of NHS Diabetes Eye Screening (screening register drawn from practices)
9 - Digital Retinal Screening
Photographic eye test for eye risk
1,2 . Please see full list of footnotes in the definitions and footnote section (page 36)
12. All Eight Care Processes
12
Key Findings
People with Type 1 diabetes are less likely than people with Type
2 diabetes to receive all of the eight care processes.
Figure 1: Percentage of people with diabetes in England and Wales receiving all
eight NICE recommended care processes by diabetes type and audit year
42.4 43.3 43.2 40.8
44.5
38.7
61.1 62.3 62.1 61.2
67.6
58.7
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15
Type 1 Type 2 and other³
Percentage
3. Please see full list of footnotes in the definitions and footnote section (page 36)
13. Care Processes – Time Series
13
Key Finding
Blood tests (Hba1c, serum creatinine, cholesterol) and blood
pressure are more reliably performed than other care processes.
Table 3: Percentage of people with diabetes in England and Wales receiving NICE
recommended care processes by care process, diabetes type and audit year
Type 1 Type 2 and other3
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15
HbA1c 85.7 86.0 83.0 79.8 80.9 83.2 92.7 93.1 90.9 93.1 93.5 94.8
Blood pressure 88.9 88.7 88.4 87.7 87.0 89.0 95.8 95.7 95.6 95.4 94.9 96.1
Cholesterol 79.1 78.8 77.8 77.3 77.4 78.7 92.9 92.8 92.1 91.9 92.4 92.8
Serum creatinine 81.0 81.2 81.1 80.3 78.8 80.5 93.6 93.5 93.5 93.2 93.4 94.5
Urine albumin*
56.2 58.4 59.2 56.5 63.9 55.9 73.9 76.7 77.5 74.7 84.4 74.6
Foot surveillance 71.7 71.5 72.8 71.5 70.7 72.4 85.3 85.5 86.4 85.8 86.2 86.7
BMI 83.6 83.4 83.7 83.3 76.8 74.9 90.8 90.5 90.9 90.9 85.7 83.1
Smoking 80.8 78.6 79.0 79.2 77.4 77.9 87.5 85.4 85.7 86.3 85.5 85.2
Eight care
processes 4 42.4 43.3 43.2 40.8 44.5 38.7 61.1 62.3 62.1 61.2 67.6 58.7
* There is a ‘health warning’ regarding the screening test for early kidney disease (Urine Albumin Creatinine Ratio, UACR) prior to 2013-14; please see the NDA Data Quality
statement
3,4. Please see full list of footnotes in the definitions and footnote section (page 36)
14. Care Processes – People with Type 1 Diabetes
14
Figure 2: Percentage of people with Type 1 diabetes in England and Wales receiving
certain care processes by audit year
Key Findings
Care process completion for blood pressure and HbA1c are
stable. BMI measurement was stable but has declined. Urine
albumin declined between 2013-14 and 2014-15.
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15
Percentage
Audit year
Blood pressure
HbA1c
BMI
Urine albumin
* There is a ‘health warning’ regarding the screening test for early kidney disease (Urine Albumin Creatinine Ratio, UACR) prior to 2013-14; please see the NDA Data Quality
statement
15. Care Processes – People with Type 2 Diabetes
15
Figure 3: Percentage of people with Type 2 and other diabetes in England and
Wales receiving certain care processes by audit year
Key Findings
Care process completion for blood pressure and HbA1c are
stable. BMI measurement was stable but has declined. Urine
albumin declined between 2013-14 and 2014-15.
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15
Percentage
Audit year
Blood pressure
HbA1c
BMI
Urine albumin
* There is a ‘health warning’ regarding the screening test for early kidney disease (Urine Albumin Creatinine Ratio, UACR) prior to 2013-14; please see the NDA Data Quality
statement
16. Care Processes – By Age
16
Key Finding
People with Type 1 and Type 2 diabetes aged under 40 are less
likely to receive all their annual care processes.
Figure 4: Percentage of all people with diabetes in England and Wales receiving all
eight NICE recommended care processes4 by age and diabetes type, in 2014-15
27.3
44.4
58.0
51.1
40.8
54.8
64.7
56.9
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Under 40 40 to 64 65 to 79 80 and over Under 40 40 to 64 65 to 79 80 and over
Type 1 Type 2 and other³
Percentage
Diabetes type
3,4. Please see full list of footnotes in the definitions and footnote section (page 36)
17. Locality Variation: Care Processes, Type 1 Diabetes
17
Key Finding
For people with Type 1 diabetes there is a large variation in care
process completion performance between CCGs or LHBs.
Figure 5: The range of CCG/LHB care process completion for
people with Type 1 diabetes in England and Wales, 2014-15
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
All eight care processes
Smoking
BMI
Foot surveillance
Urine albumin
Serum creatinine
Cholesterol
Blood pressure
HbA1c
Percentage of patients
Care
process
3. Please see full list of footnotes in the definitions and footnote section (page 36)
18. Locality variation: Care Processes, Type 2 diabetes
18
Key Finding
For people with Type 2 diabetes blood tests (Hba1c, cholesterol
and serum creatinine) and blood pressure checks are performed
much more reliably than other care processes.
Figure 6: The range of CCG/LHB care process completion for
people with Type 2 diabetes in England and Wales, 2014-15
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
All eight care processes
Smoking
BMI
Foot surveillance
Urine albumin
Serum creatinine
Cholesterol
Blood pressure
HbA1c
Percentage of patients
Care
process
3. Please see full list of footnotes in the definitions and footnote section (page 36)
19. Care Processes – CCG/LHB distribution
This slide has been left blank for CCG/LHB or GP Practices to insert CCG/LHB or GP level information
from the GP level excel spreadsheet.
For example:
• You may choose to show Chart X from the spreadsheet this will provide you with the spread of performance
across a particular CCG/LHB
19
20. Care Process – Two Example GP Practices
This slide has been left blank for CCG/LHB or GP Practices to insert CCG/LHB or GP level information
from the GP level excel spreadsheet.
For example:
• You may choose to show two contrasting GP practices in your area from the spreadsheet
• You may want to add here the differences in the processes for the two practices and any
improvements made.
20
21. Care Processes: Comment
BMI measurement fell in 2013-14 and urine albumin checks
dropped in 2014-15. These changes may reflect retirement of
the respective QOF indicators and a consequent change in focus
for GP practices.
Care process completion rates still vary appreciably between
localities, between practices within localities, between Type 1
and Type 2 diabetes and by age. Encouragingly, however, the
range of variation is narrowing.
21
Recommendations:
• CCGs and LHBs should network and learn about which systems
best support high levels of care process delivery
• Within localities practices should be encouraged to share
successful care process delivery systems
• Commissioners should consider the impact on core diabetes
care of changing pay for performance mechanisms such as QOF
22. Structured Education
Key Findings
There has been a large increase in records of structured education
being offered within one year of diagnosis.
More people with Type 2 diabetes are recorded as being offered
education (78%) than people with Type 1 (32%).
22
Figure 7: Percentage of people newly diagnosed with diabetes being offered structured
education in England and Wales by audit year
7.6 10.3 11.5
15.9
66.5
75.8
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15
Percentageofnewlydiagnosed
diabetics
Audit Year
23. Structured Education – A Patients View
Records of attending structured education have increased only slightly from 3.4 per cent in 2012-13
to 5.3 per cent in 2014-15. People with diabetes want and need education to manage their condition.
23
Recommendations
Commissioners and providers of diabetes care should investigate the
reasons for the increased disparity between structured education offers and
structured education attendances.
The focus of all should be on how to increase the number of people who
attend structured education. The value is evident in the quotes.
Malcolm, 69 years old, has Type 2 – attended a DESMOND course Charlotte, 27 years old, has Type 1 – attended a DAFNE course
Grant, has Type 1, 53 years old – attended a DAFNE course
“Meeting other people with diabetes was a real strong
point of DAFNE. Being able to talk to other people who
had the same sort of fears made me feel a lot more
able to confront them. What I found the course really
good for was that dedicated time to reflect on what is
actually going on and getting to know my diabetes
again. I left feeling more in control of my own life”
“Going on the DESMOND course made a big difference.
It took the worry away. It reduced my HbA1c. It reduced
my cholesterol. I lost three stone in weight. My blood
pressure came down. I am still scuba diving at the age of
69. Now I understand the condition I don't worry. It doesn't
stop me doing anything I want to do.”
“I have lived with type 1 diabetes for over 20 years, yet only received education when I was placed on an insulin pump. What
I learnt about carb counting was invaluable, and if I had known that 20 years ago it would have changed how I self-
managed”.
24. National Diabetes Audit
24
What percentage of people
registered with diabetes
achieved NICE defined
treatment targets for glucose
control, blood pressure and
blood cholesterol?
25. Treatment Targets
25
NICE recommends treatment targets for HbA1c
(glucose control), blood pressure and serum
cholesterol
• Target HbA1c reduces the risk of all diabetic
complications
• Target blood pressure reduces the risk of vascular
complications and reduces the progression of eye
disease and kidney failure.
• Target cholesterol reduces the risk of vascular
complications
26. Treatment Target – Time Series
26
Key Findings:
For people with Type 2 diabetes, HbA1c and cholesterol target achievement
rates are stable but blood pressure target achievement rates have improved
steadily.
For those with Type 1 diabetes, cholesterol target achievement rates have
been stable, HbA1c may show a slight improvement but blood pressure
target achievement has improved steadily.
Type 1 Type 2 and other
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15
HbA1c
< 58 mmol/mol 28.7 28.1 27.0 27.2 29.4 29.9 66.6 66.5 65.8 64.9 66.8 66.1
Blood Pressure
< 140/80* 68.5 68.8 72.2 73.4 76.4 76.4 60.8 61.4 66.6 68.6 73.6 74.2
Cholesterol
< 5mmol/L 72.6 72.0 71.1 70.2 71.5 71.3 78.2 78.0 77.4 76.7 77.8 77.5
Meeting all three
treatment targets 16.9 16.5 16.5 16.1 18.6 18.9 35.0 35.1 37.4 37.3 41.4 41.0
Table 4: Percentage of people with diabetes in England and Wales achieving their treatment targets by
diabetes type and audit year
* The blood pressure target does not exactly match NICE (<140/80) but was changed to align with the relevant QOF indicator (<140/80) . More information can be found here
27. Treatment Target – Blood Pressure
Key Finding
Blood pressure treatment target achievement (<140/80) has
been steadily improving over time.
27
Figure 8: Blood pressure treatment target achievement rate for people with diabetes in England
and Wales by diabetes type and audit year
68.5 68.8
72.2 73.4
76.4 76.4
60.8 61.4
66.6 68.6
73.6 74.2
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15
Type 1 Type 2 and other³
Percentage
3. Please see full list of footnotes in the definitions and footnote section (page 36)
28. Treatment Target – By Age
28
Key Finding:
People aged under 65 with either Type 1 or Type 2 diabetes are
much less likely to achieve the NICE treatment targets.
Figure 9: Percentage of all people with diabetes in England and Wales achieving all three treatment
targets (HbA1c<58 and BP<140/80 and Cholesterol<5) by diabetes type and age group, 2014-15
18.1 17.0
25.5 26.9 27.2
32.8
46.7 49.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Under 40 40 to 64 65 to 79 80 and over Under 40 40 to 64 65 to 79 80 and over
Type 1 Type 2 and other³
Percentage
Diabetes type
3 Please see full list of footnotes in the definitions and footnote section (page 36)
29. Local Variation - Treatment Target – Type 1 Diabetes
29
Key Finding
For people with Type 1 diabetes there is a large variation in
treatment target performance between CCGs and LHBs.
Figure 10: The range of CCG/LHB treatment target achievement
for people with Type 1 diabetes in England and Wales, 2014-15
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Meet all treatment targetsᶜ
Cholesterol <5mmol/L
BP <=140/80ᵇ
HbA1c ≤58mmol/mol (7.5%)
Percentage of patients achieving target
Treatment target
30. Local variation - Treatment Target – Type 2 Diabetes
30
Key Finding
For people with Type 2 diabetes the range of variation in treatment
target achievement is still appreciable but less than for people with
Type 1.
Figure 11: The range of CCG/LHB treatment target achievement
for people with Type 2 and other diabetes in England and Wales, 2014-15
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Meet all treatment targetsᶜ
Cholesterol <5mmol/L
BP <=140/80ᵇ
HbA1c ≤58mmol/mol (7.5%)
Percentage of patients achieving target
Treatment target
31. Treatment Targets– CCG/LHB distribution
This slide has been left blank for CCG/LHB or GP Practices to insert CCG/LHB or GP level information
from the GP level excel spreadsheet.
For example:
• You may choose to show Chart X from the spreadsheet this will provide you with the spread of performance
across a particular CCG/LHB
31
32. Treatment Targets– Two Example GP Practices
This slide has been left blank for CCG/LHB or GP Practices to insert CCG/LHB or GP level information
from the GP level excel spreadsheet.
For example:
• You may choose to show two contrasting GP practices in your area from the spreadsheet
• You may want to add here the differences in the processes for the two practices and any
improvements made.
32
33. Treatment Targets: Comment
The improvement in blood pressure results, prioritised for
improvement in earlier NDA reports, are an important and
substantial achievement. They will mean fewer heart
attacks and strokes and less acceleration of eye and
kidney disease.
However, blood glucose control remains high risk in most
people with Type 1 diabetes and in all younger people with
diabetes.
33
Recommendations:
• Continue to prioritise improved blood pressure management
• Seek out better ways of achieving lower risk blood glucose
levels in people with diabetes of working age and younger
• Foster local and regional networks to share successful systems
of care and reduce variation
35. Definitions
35
Diabetes is a condition where the amount of glucose in the blood is too high because the pancreas doesn’t produce enough
insulin. Insulin is a hormone produced by the pancreas that allows glucose to be used as a body fuel and other nutrients to be
used as building blocks. There are two main types of diabetes: Type 1 diabetes (no insulin); Type 2 diabetes (insufficient insulin)
Care Processes (NICE recommends all of these at least once a year)
Blood Pressure is a measurement of the force driving the blood through the arteries. Blood pressure readings contain two
figures, e.g.130/80. The first is known as the systolic pressure which is produced when the heart contracts. The second is the
diastolic pressure which is when the heart relaxes to refill with blood.
BMI measurement – Body Mass Index calculated from weight and height to classify under, normal and over-weight
Serum creatinine – this blood test is used as measure kidney function
Urinary albumin – this urine test detects the earliest stages of kidney disease
Cholesterol - this blood test measures a type of fat that can damage blood vessels
Foot check - this examination checks the blood supply and sensation (feeling) in the feet. Loss of either is a risk for foot disease
Smoking Status - this records whether the person is a smoker. Smoking increases the diabetic risk for heart attacks and stroke
HbA1c – this is a blood test for average blood glucose levels during the previous two to three months.
Treatment Targets (NICE defines target levels to reduce risks of complications for people with
diabetes)
HbA1c - the closer this is to normal (less than 42mmol/mol) the lower is the risk of all long term complications of diabetes
Cholesterol – reducing cholesterol levels lowers the risk of heart attacks and strokes
Blood Pressure – high levels are a risk for heart attacks and strokes; they also drive progression of eye and kidney disease
Specialist Service
This is a service (often hospital based but sometimes delivered in a community setting) which includes diabetes specialists
working in multidisciplinary teams. These teams usually comprise physicians (Diabetologists), Diabetes Specialist nurses and
dieticians; it may also include clinical psychologists.
36. Footnotes
1. NICE recommended care processes http://www.nice.org.uk/guidance/conditions-and-diseases/diabetes-and-other-
endocrinal--nutritional-and-metabolic-conditions/diabetes
2. National Service Framework (NSF) for Diabetes https://www.gov.uk/government/publications/national-service-framework-
diabetes
NICE Clinical Guidelines – GN17: Type 1 diabetes in adults: diagnosis and management
http://www.nice.org.uk/guidance/ng17
NICE Clinical Guidelines – NG28: Type 2 diabetes in adults: management http://www.nice.org.uk/guidance/ng28
NICE – Diabetes in Adults Quality Standard http://guidance.nice.org.uk/QS6
3. Type 2 diabetes includes people with MODY, other and non specified diabetes type.
4. The eye screening care process is not included in this table; therefore ‘eight care processes’ comprises the eight care
processes that are listed above.
36
37. Additional Information
For more information and the accompanying excel
documents and data please visit the HSCIC website.
http://www.hscic.gov.uk/pubs/ndauditcorerep1415
National Report (pdf)
Power point slide set
Excel version of the tables and charts found in this report
The GP practice level data spreadsheet for England, including an interactive
report
The Local Health Board level data spreadsheet for Wales, including an
interactive report
The Specialist Service level data spreadsheet for participating services,
including an interactive report
The data quality statement
The methodology document
37
38. 38
Prepared in collaboration with:
Supported by:
The Healthcare Quality Improvement Partnership (HQIP). The National Pregnancy in Diabetes
Audit is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the
National Clinical Audit Programme (NCA). HQIP is led by a consortium of the Academy of
Medical Royal Colleges, the Royal College of Nursing and National Voices. Its aim is to promote
quality improvement, and in particular to increase the impact that clinical audit has on
healthcare quality in England and Wales. HQIP holds the contract to manage and develop the
NCA Programme, comprising more than 30 clinical audits that cover care provided to people
with a wide range of medical, surgical and mental health conditions. The programme is funded
by NHS England, the Welsh Government and, with some individual audits, also funded by the
Health Department of the Scottish Government, DHSSPS Northern Ireland and the Channel
Islands.
The Health and Social Care Information Centre (HSCIC) is the trusted source of authoritative
data and information relating to health and care. The HSCIC managed the publication of the
annual report.
Diabetes UK is the largest organisation in the UK working for people with diabetes, funding
research, campaigning and helping people live with the condition.
The national cardiovascular intelligence network (NCVIN) is a partnership of leading
national cardiovascular organisations which analyses information and data and turns it
into meaningful timely health intelligence for commissioners, policy makers, clinicians
and health professionals to improve services and outcomes.